Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout Program
MT newswire2026/10/08 20:5604:56 PM EDT, 10/08/2026 (MT Newswires) -- Xortx Therapeutics (XRTX) shares rose 22% in after-hours trading after the company said it has received inquiries from potential commercialization partners for its XRx-026 gout program, though it has not entered into any agreements. The company said Thursday its planned Clinical Trial Application submission to Health Canada would support a two-part clinical study, XRX-OXY-102, evaluating Xorlo, its proprietary oxypurinol formulation, for the treatment of gout. Xortx said that conducting the first part of the study in Canada could accelerate key clinical data needed for a planned new drug application with the US Food and Drug Administration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Crypto prices
More
